SCHEMBL426433

SCHEMBL426433

CCCc1ccc(O)c(OCC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.58
CNR2 P34972 1/20 0.58
ALDH1A1 P00352 4/20 0.54
TSHR P16473 3/20 0.54
KDM4E B2RXH2 3/20 0.54
KMT2A Q03164 3/20 0.51
TAAR1 Q96RJ0 2/20 0.51
MEN1 O00255 2/20 0.51
MAPK1 P28482 1/20 0.51
GAA P10253 2/20 0.50
MAPT P10636 2/20 0.50
ALOX15 P16050 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
POLB P06746 1/20 0.50
XBP1 P17861 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
LMNA P02545 1/20 0.50
GLA P06280 1/20 0.50
GABRA1 P14867 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20399514 0.89 ALDH1A1 (0.51) ALDH1A1TSHRKDM4EKMT2ATAAR1
SCHEMBL20399450 0.88 KAT8 (0.53) ALDH1A1TSHRKDM4E
SCHEMBL12788915 0.87 TSHR (0.69) ALDH1A1TSHRKDM4EKMT2ATAAR1
SCHEMBL6809980 0.87 ALDH1A1 (0.55) ALDH1A1TSHRKDM4EKMT2ATAAR1
SCHEMBL10757759 0.86 ALDH1A1 (0.51) ALDH1A1TSHRKDM4EKMT2ATAAR1
SCHEMBL18328794 0.86 ALDH1A1 (0.51) ALDH1A1TSHRKDM4EKMT2ATAAR1
SCHEMBL27935838 0.86 ALDH1A1 (0.51) ALDH1A1TSHRKDM4EKMT2ATAAR1
SCHEMBL532205 0.85 CNR1 (0.53) CNR1CNR2TSHRKDM4EKMT2A
SCHEMBL10762625 0.85 TRPA1 (0.57) ALDH1A1TSHRKDM4EKMT2ATAAR1
SCHEMBL586875 0.83 ALDH1A1 (0.55) ALDH1A1TSHRKDM4EKMT2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3303276-B1 PRODUCTION OF 3-ALKYLPHENOLS UNIV LEUVEN KATH (BE) 2023-04-12 EP claimed
EP-4103576-A1 3'-KETOGLYCOSIDE COMPOUND FOR THE SLOW RELEASE OF A VOLATILE ALCOHOL Glycoscience, S.L. (ES) 2022-12-21 EP claimed
WO-2021160670-A1 3'-KETOGLYCOSIDE COMPOUND FOR THE SLOW RELEASE OF A VOLATILE ALCOHOL GLYCOSCIENCE, S.L. (ES) 2021-08-19 WO claimed
EP-3571180-B1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF UNIV LEUVEN KATH (BE) 2024-12-18 EP disclosed
EP-3303276-B1 PRODUCTION OF 3-ALKYLPHENOLS UNIV LEUVEN KATH (BE) 2023-04-12 EP disclosed
US-20210070684-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2021-03-11 US disclosed
US-10869822-B2 Compositions for treatment of dermatological diseases and conditions and methods of use thereof DermaMedics, LLC (US) 2020-12-22 US disclosed
EP-3571180-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF Katholieke Universiteit Leuven (BE) 2019-11-27 EP disclosed
US-20180235859-A1 Compositions for Treatment of Dermatological Diseases and Conditions and Methods of Use Thereof DermaMedics, LLC 2018-08-23 US disclosed
WO-2018134427-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2018-07-26 WO disclosed
US-9980887-B2 Compositions for use in treatment of hyperpigmentation and methods of use thereof DermaMedics, LLC (US) 2018-05-29 US disclosed
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-03-15 US disclosed
US-8058445-B2 Substituted pyridinecarboxamides for the treatment of cancer AMGEN INC. (US) 2011-11-15 US disclosed
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases PFIZER, INC. 2011-02-24 US disclosed
US-20100298369-A1 BERBAMINE DERIVATIVES CITY OF HOPE 2010-11-25 US disclosed
EP-2244690-A1 METHODS AND COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES AND CONDITIONS Therametics, Llc (US) 2010-11-03 EP disclosed
US-20100249244-A1 METHODS AND COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES AND CONDITIONS THERAMETICS, LLC 2010-09-30 US disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
WO-2009049172-A1 METHODS AND COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES AND CONDITIONS THERAMETICS, LLC (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298369-A1 BERBAMINE DERIVATIVES BAK1, MCL1, BAD CNR1 2649/4885CNR2 2986/4885ALDH1A1 1755/4885
US-20210070684-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF MMS19, PCBP1, PBRM1 CNR1 1840/4885CNR2 1956/4885ALDH1A1 1877/4885
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AADAC, NAT1, PIGO CNR1 46/4885CNR2 22/4885ALDH1A1 327/4885
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases SNCA, PARK7, HTT CNR1 952/4885CNR2 1320/4885ALDH1A1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.